Jaguar Health, Inc. (JAGX) · Oct 28, 2026 · Share issuance

Jaguar Health stock plan expands sixfold after preferred dividend

Six-fold plan expansion — 2,273,154 shares if Proposal 3 passes, versus 378,859 previously

Jaguar Health’s stock plan reserve will rise sixfold after the Series R dividend, preserving a 14% share while expanding potential employee dilution.

Jaguar is shifting its business toward rare-disease development of crofelemer for intestinal-failure indications, after licensing its commercialized products to Future Pak; its stated pipeline goal is an MVID NDA filing in mid-2027. This filing is a capital-structure adjustment, not a clinical or operating milestone. The Series R preferred-stock dividend and its planned five-for-one common-stock conversion were already disclosed, so the new information is how Jaguar is resizing employee-equity capacity around that dilution. 〔0〕

Plan metricBefore adjustment / prior proposalAfter adjustmentFiling reference
Shares available under 2014 Plan710 shares; 0.14%2,273,154 shares if Proposal 3 passes(Background; Share Reserve Adjustment)
Proposed reserve before adjustment378,859 shares; 14%—(Proposal 3; Share Reserve Adjustment)
Incentive-stock-option limit27,333 shares163,998 shares(Share Reserve Adjustment)
If Proposal 3 fails710 shares4,260 shares(Share Reserve Adjustment)

The six-fold increase preserves the percentage, not the absolute dilution. Jaguar says the reserve should remain approximately 14% of fully diluted shares after the Series R conversion, but that requires expanding the authorization from 378,859 shares to 2,273,154 if shareholders approve Proposal 3. 〔1〕 That is mechanically understandable after the share-count expansion, but it also creates a much larger pool of shares that could eventually be issued as compensation.

The immediate business impact is limited, but the governance signal is meaningful. The filing does not issue the 2.27 million shares, improve funding, or advance crofelemer development; it keeps the equity-incentive plan scaled to the enlarged capitalization. The six-fold reset is therefore partly known through the previously announced Series R transaction, while the exact size of the refreshed reserve is new. 〔2〕

Bottom line: This is mostly a mechanical proxy update, but it confirms that Jaguar’s post-Series R capital structure will support a substantially larger potential equity pool. It matters for dilution and shareholder voting, not for the underlying rare-disease program itself.

What to watch next

Series R conversion, November 2

Original filing on SEC EDGAR

More Jaguar Health, Inc. news

Jaguar Health stock plan expands sixfold after preferred dividend | JAGX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.